GlassScriptPhysician profile
Allen Cooke
NPI 1851909162
$6,916.86
in general payments reported to CMS, 2019-2025
48 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,022 · 2022: $1,337 · 2023: $1,830 · 2024: $1,507 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,533 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,532.79 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,652.18 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,104.94 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $486.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $343.72 | 2022-2025 | Repatha, Otezla, Krystexxa |
| Lilly USA, LLC | $219.50 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $217.95 | 2022 | |
| Corium, LLC | $206.29 | 2022-2023 | Azstarys |
| Glaxosmithkline, LLC. | $202.30 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $185.13 | 2021-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $180.89 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.98 | 2021-2024 | Synjardy, Jardiance, Tradjenta |
| Pfizer INC. | $165.09 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $138.64 | 2024 | Voquezna |
| Exact Sciences Corporation | $121.46 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $117.50 | 2023-2025 | Quviviq, Quviviq |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $103.03 | 2021-2022 | |
| Tolmar, INC. | $93.10 | 2024-2025 | Jatenzo |
| Lucid Diagnostics INC. | $89.84 | 2023 | |
| Boston Scientific Corporation | $89.56 | 2023-2025 | Wavewriter Alpha Prime 16, Spectra Wavewriter |
| Mayne Pharma Commercial LLC | $88.33 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $76.80 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $67.09 | 2022-2024 | |
| Antares Pharma, INC. | $65.73 | 2024-2025 | Xyosted |
| Lundbeck LLC | $62.09 | 2022-2023 | Rexulti |
| Sumitomo Pharma America, INC. | $53.28 | 2023-2025 | Gemtesa |
| Corcept Therapeutics | $50.18 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $42.60 | 2021-2024 | Nexletol |
| Shield Therapeutics INC | $41.93 | 2022-2023 | Accrufer |
| Clarus Therapeutics INC. | $41.80 | 2021 | |
| Currax Pharmaceuticals LLC | $40.43 | 2023 | Nexletol, Contrave |
| Otsuka America Pharmaceutical, INC. | $40.06 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $36.55 | 2021-2022 | |
| Stryker Corporation | $31.44 | 2025 | Clottriever Bold Catheter |
| Halozyme INC | $30.72 | 2023 | |
| Astellas Pharma US INC | $26.37 | 2024 | Veozah |
| Eisai INC. | $26.17 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $23.67 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.55 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.34 | 2023 | Gvoke Hypopen |
| Edwards Lifesciences Corporation | $18.41 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Viatris Specialty LLC | $18.37 | 2025 | Yupelri |
| Endo Pharmaceuticals INC. | $17.48 | 2021 | |
| Merck Sharp & Dohme LLC | $15.56 | 2025 | Gardasil 9, Capvaxive |
| Teva Pharmaceuticals USA, INC. | $15.35 | 2022 | |
| Acerus Pharmaceuticals Corporation | $15.25 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.51 | 2021 | |
| Verity Pharmaceuticals INC. | $13.95 | 2025 | Tlando |
| Sonex Health, INC. | $8.20 | 2025 | Sx-One Microknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Cooke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.